TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Century Therapeutics
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

Century Therapeutics has developed an innovative iPSC-derived beta islet therapy (CNTY-813) for Type 1 Diabetes, engineered with Allo-Evasion™ 5.0 technology to potentially provide durable glucose control without chronic immunosuppression. Preclinical data shows promising results in glucose normalization and immune protection.

Insights
IPSC   positive

Company announced a breakthrough therapeutic approach for Type 1 Diabetes with compelling preclinical data, potential for a curative therapy, and plans for IND submission by 2026